References

Adelman DC, Casale TB, Corren J. Manual of allergy and immunology.Philadelphia: Wolters Kluwer; 2012

Becskei C, De Bock F, Illambas J Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™), for the treatment of sarcoptic mange in dogs. Vet Parasitol. 2016; 222:56-61 https://doi.org/10.1016/j.vetpar.2016.02.017

Beugnet F, Bourdeau P, Chalvet-Monfray K Parasites of domestic owned cats in Europe: co-infestations and risk factors. Parasit Vect. 2014; 7 https://doi.org/10.1186/1756-3305-7-291

Beugnet F, Franc M. Insecticide and acaricide molecules and/or combinations to prevent pet infestation by ectoparasites. Trends Parasitol. 2012; 28:(7)267-279 https://doi.org/10.1016/j.pt.2012.04.004

Beugnet F, Halos L, Lebon W, Liebenberg J. Assessment of the efficacy of a topical combination of fipronil-permethrin (Frontline Tri-Act®/Frontect®) against egg laying and adult emergence of the cat flea (Ctenocephalides felis) in dogs. Parasite. 2016; 23 https://doi.org/10.1051/parasite/2016068

Bitam I, Dittmar K, Parola P Fleas and flea-borne diseases. Int J Infect Dis. 2010; 14:(8)667-676 https://doi.org/10.1016/j.ijid.2009.11.011

Conboy G. Cestodes of dogs and cats in North America. Vet Clin North Am: Small Animal Pract. 2009; 39:(6)1075-1090 https://doi.org/10.1016/j.cvsm.2009.06.005

Dyer F, Diesel G, Cooles S, Tait A. Suspected adverse reactions, 2009. Vet Rec. 2010; 167:(4)118-121 https://doi.org/10.1136/vr.c3650

Dryden MW, Payne PA, Smith V Evaluation of indoxacarb and fipronil (s)-methoprene topical spot-on formulations to control flea populations in naturally infested dogs and cats in private residences in Tampa FL, USA. Parasit Vect. 2013; 6

Food and Drug Administration. Food and Drug Administration Original Approval for Program 6 Month Injectable for Cats. 1998. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/2222

Geurden T, Becskei C, Farkas R Efficacy and safety of a new spot-on formulation of selamectin plus sarolaner in the treatment of naturally occurring flea and tick infestations in cats presented as veterinary patients in Europe. Vet Parasitol. 2017; 238:S12-S17 https://doi.org/10.1016/j.vetpar.2017.03.008

Gunnarsson L, Christensson D, Palmer E. Clinical efficacy of selamectin in the treatment of naturally acquired infection of sucking lice (Linognathus setosus) in dogs. J Am Anim Hosp Assoc. 2005; 41:388-94

Kilp S, Ramirez D, Allan MJ Comparative pharmacokinetics of fluralaner in dogs and cats following single topical or intravenous administration. Parasit Vectors. 2016; 9

Maddison JE, Page SW, Church D. Small animal clinical pharmacology.Edinburgh: Saunders/Elsevier; 2008

Maynard L, Houffschmitt P, Lebreux B. Field efficacy of a 10 per cent pyriproxyfen spot-on for the prevention of flea infestations on cats. J Small Anim Practice. 2001; 42:491-4

Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations. Parasit Vect. 2014; 7

Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations. Parasit Vect. 2017; 10

Malik R, Ward MP, Seavers A Permethrin spot-on intoxication of cats: literature review and survey of veterinary practitioners in Australia. J Feline Med Surg. 2010; 12:(1)5-14 https://doi.org/10.1016/j.jfms.2009.12.002

Mencke N. Future challenges for parasitology: vector control and ‘One health’ in Europe: the veterinary medicinal view on CVBDs such as tick borreliosis, rickettsiosis and canine leishmaniosis. Vet Parasitol. 2013; 195:(3-4)256-271 https://doi.org/10.1016/j.vetpar.2013.04.007

Palmieri V, Dodds WJ, Morgan J Survey of canine use and safety of isoxazoline parasiticides. Vet Med Sci. 2020; 6:(4)933-945

Pollmeier M, Pengo G, Jeannin P, Soll M. Evaluation of the efficacy of fipronil formulations in the treatment and control of biting lice, Trichodectes canis (De Geer, 1778) on dogs. Vet Parasitol. 2002; 107:(1–2)127-136 https://doi.org/10.1016/S0304-4017(02)00090-0

Rafiqi SI, Kumar S, Chaudhary R Ectoparasites of companion animals and their control. Trends Vet Animal Sci. 2016; 3:15-18

Reker D, Blum SM, Steiger C “Inactive” ingredients in oral medications. Sci Transl Med. 2019; 11:(483) https://doi.org/10.1126/scitranslmed.aau6753

Rivera P, Akerlund-Denneberg N, Bergvall K Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas. J Small Anim Pract. 2013; 54:(1)20-27 https://doi.org/10.1111/j.1748-5827.2012.01304.x

Rohdich N, Roepke RK, Zschiesche E. A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto (fluralaner) against Frontline (fipronil) in flea- and tick-infested dogs. Parasit Vect. 2014; 7

Rust MK, Dryden MW. The biology, ecology, and management of the cat flea. Annu Rev Entomol. 1997; 42:(1)451-473 https://doi.org/10.1146/annurev.ento.42.1.451

Six RH, Clemence RG, Thomas CA Efficacy and safety of selamectin against Sarcoptes scabiei on dogs and Otodectes cynotis on dogs and cats presented as veterinary patients. Vet Parasitol. 2000; 91:291-309

Turner V, Chaffey C, Ferrao P. A survey for small animal veterinarians regarding flea and tick control pesticide products. Can Vet J. 2011; 52:(10)1080-1082

Varloud M, Hodgkins E. Five-month comparative efficacy evaluation of three ectoparasiticides against adult cat fleas (Ctenocephalides felis), flea egg hatch and emergence, and adult brown dog ticks (Rhipicephalus sanguineus sensu lato) on dogs housed outdoors. Parasitol Res. 2015; 114:(3)965-973 https://doi.org/10.1007/s00436-014-4262-5

Wengenmayer C, Williams H, Zschiesche E The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs. Parasit Vect. 2014; 7 https://doi.org/10.1186/s13071-014-0525-3

Witchey-Lakshmanan LC. Long-acting control of ectoparasites: a review of collar technologies for companion animals. Adv Drug Del Rev. 1999; 38:(2)113-122 https://doi.org/10.1016/S0169-409X(99)00011-3

A snapshot of the adverse effects of companion animal ectoparasiticides

02 July 2021
15 mins read
Volume 26 · Issue 7
Figure 1. A flow chart depicting how many articles were included or excluded in the search for adverse drug events associated with the use of ectoparasiticides analysed in the present study.
Figure 1. A flow chart depicting how many articles were included or excluded in the search for adverse drug events associated with the use of ectoparasiticides analysed in the present study.

Abstract

The burden of ectoparasitic infestations is aggravated by the lack of vaccines and the inability to prevent the most serious vector-borne infections. This makes the administration of effective and safe ectoparasiticide drugs vital for prevention and treatment. However, adverse clinical consequences of treatment with ectoparasiticides affect many companion animals in the UK each year. In this study, information about the frequency of adverse drug events associated with the use of some ectoparasiticides in dogs and cats was collected, from data obtained from The National Office of Animal Health compendium datasheets and data available from published studies. Different ectoparasiticides were associated with different prevalences and types of adverse dermatological, gastrointestinal and neurological events. The heterogeneity between studies and the lack of field safety data for some products precludes head-to-head comparison of adverse events associated with ectoparasiticide treatment between studies. Therefore, caution should be exercised about making any conclusions when comparing ectoparasiticides. However, the data indicated an association between ectoparasiticide treatment and adverse events and demonstrated that this association can vary across different drug administration routes and classes. The low number of observations of the adverse drug events, relative to the number of administered doses, confirms that the health benefits of ectoparasiticides far outweigh the potential risks associated with their use. Further research is required on how adverse drug events can be predicted and prevented.

Infestations by ectoparasites represent a significant threat to the health and welfare of dogs and cats. Ectoparasites can cause various dermatological signs, such as pruritus, allergies and even anaemia in heavy infestations (Beugnet et al, 2014). As an example, fleas can cause irritation, pruritus, hair loss and flea allergy dermatitis (Varloud and Hodgkins, 2015). Fleas can also act as vectors of pathogens such as Rickettsia spp. and Bartonella spp. and can serve as the intermediate host of the tapeworm Dipylidium caninum (Conboy, 2009; Bitam et al, 2010). Lice infestations can result in intense irritation, pruritus, and self-trauma. Scratching can lead to alopecia, crusts and secondary bacterial involvement (Pollmeier et al, 2002). Lice can also act as vectors for various disease-causing pathogens and, like fleas, the chewing louse (Trichodectes canis) can serve as an intermediate host of D. caninum. Ticks, in addition to causing irritation, feed on the blood of their host and can subsequently cause anaemia (Varloud and Hodgkins, 2015). Ticks can carry and transmit a number of pathogens while feeding on their host (Wengenmayer et al, 2014). A number of mite genera can also cause serious welfare concerns in companion animals, including Demodex, Sarcoptes, Otodectes, Notoedres and Cheyletiella (Becskei et al, 2016). Besides causing significant morbidity and mortality among companion animals, ectoparasites have a considerable economic impact because of the costs associated with treatment and control (Rafiqi et al, 2016).

Register now to continue reading

Thank you for visiting UK-VET Companion Animal and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.